Tag: Experimental drug

Fasoracetam is an experimental drug of the racetam class that was never brought to market, despite being investigated for several potential indications. While most initial development was discontinued due to a lack of broad effectiveness, recent research has focused on its potential for a specific subset of patients with genetic mutations.

As of late 2025, Trodusquemine is not approved by the U.S. Food and Drug Administration (FDA) for human use and is not commercially available in the United States. The compound remains an investigational drug, available only for research purposes through commercial suppliers.

The mitochondrial-derived peptide MOTS-c was identified in 2015, revealing a novel communication pathway for metabolic regulation originating from our cell's powerhouses. This discovery provided significant new insights into how mitochondria influence the body's overall energy balance and impact conditions like insulin resistance. The subsequent research has rapidly expanded the understanding of this peptide's far-reaching effects on systemic health.

According to manufacturers and research suppliers, **what is Adamax?** It is a synthetic peptide, derived from a variant of Semax, and is exclusively available as a research chemical, not a medication for human use. This experimental compound is being studied for its potential effects on cognitive function, endurance, and metabolic pathways.